Thermo Fisher Scientific today priced an underwritten offering of a series of euro- and dollar-denominated senior notes, in an aggregate principal amount of $5.7 billion.

The firm priced €800 million ($877.8 million) aggregate principal amount of its 0.125 percent senior notes due 2025; €800 million aggregate principal amount of its 0.5 percent senior notes due 2028; €900 million aggregate principal amount of its 0.875 percent senior notes due 2031; €900 million aggregate principal amount of its 1.5 percent senior notes due 2039; €1.0 billion aggregate principal amount of its 1.875 percent senior notes due 2049; and $900 million aggregate principal amount of its 2.6 percent senior notes due 2029.

Waltham, Massachusetts-based Thermo Fisher will use the funds to redeem two classes of senior notes with a total aggregate principal of $1.1 billion, as announced earlier this month.

Thermo Fisher will also use the funds to redeem $4.5 billion aggregate principal amount of outstanding senior notes issued by the firm or its subsidiaries, including all outstanding 6 percent senior notes due 2020 and 5 percent senior notes due 2021 issued by its Life Technologies subsidiary.

The joint book-running managers for the euro offering are Goldman Sachs, Merrill Lynch International, Citigroup Global Markets and JP Morgan. The joint book-running managers for the dollar-denominated offering are Goldman Sachs, Bank of America Securities, Credit Suisse Securities, and HSBC Securities.

The euro offering is expected to close on or about Sept. 30, and the dollar-denominated offering is expected to close on or about Oct. 8. The euro notes will pay interest on an annual basis, while the dollar-denominated notes will pay interest on a semi-annual basis.